Market Overview

UPDATE: Sterne Agee Reiterates On Intuitive Surgical Ahead Of Advisory Committee

Share:
Related ISRG
Jim Cramer Weighs In On Arch Coal, AbbVie And More
A Running List Of The Companies Blaming Trade Policy For Stifled Earnings, Guidance
Buy High Quality Stocks On Turkey-Induced Weakness - Cramer's Mad Money (8/13/18) (Seeking Alpha)

In a report published Wednesday, Sterne Agee analyst Gregory P. Chodaczek reiterated a Neutral rating on Intuitive Surgical (NASDAQ: ISRG), and raised the price target from $380.00 to $400.00.

In the report, Sterne Agee noted, “The FDA will convene a Medical Device Advisory Committee July 10-11 based on its previous safety advisory discouraging doctors from using power morcellators to remove fibroids. We believe this outcome will move from discouragement to an FDA requirement of a ‘boxed warning' related to the risk of cancer spread using power morcellation. Although we believe this warning will negatively affect Intuitive Surgical, we maintain our Neutral rating with a new price target of $400.00.”

Intuitive Surgical closed on Tuesday at $377.60.

Latest Ratings for ISRG

DateFirmActionFromTo
Aug 2018CitigroupMaintainsBuyBuy
Jul 2018Morgan StanleyMaintainsOverweightOverweight
Jul 2018Stifel NicolausMaintainsBuyBuy

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Gregory P. Chodaczek Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISRG)

View Comments and Join the Discussion!

Benzinga's Top Downgrades

The Queen Announces That Restraints On Business Will Be Cut